Cellectar Biosciences (CLRB) Cash from Operations (2010 - 2025)
Cellectar Biosciences (CLRB) posted Cash from Operations of 4344136.0 for Q4 2025, down 1.61% sequentially from 4275121.0 in Q3 2025, and up 60.19% YoY from 2711784.06 in Q4 2024.
Cellectar Biosciences (CLRB) Cash from Operations (2010 - 2025) Analysis & Trends
Cellectar Biosciences has reported Cash from Operations for 16 years, with the latest figure at 4344136.0 in Q4 2025.
- Quarterly Cash from Operations rose 60.19% year-over-year to 4344136.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 23118217.0 (up 51.41% YoY) and the FY2025 annual result came in at 23118217.0, up 51.41% from the prior year.
- Cash from Operations retreated to 4344136.0 in Q4 2025 per CLRB's latest filing, from 4275121.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 4275121.0 in Q3 2025 and troughed at 14140999.0 in Q2 2024.
- A 5-year average of 7543466.55 and a median of 7098423.5 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2021 and 2025: Cash from Operations tumbled 125.46% in 2021, then soared 63.82% in 2025.
- Over 5 years, Cash from Operations stood at 4511012.0 in 2021, then tumbled by 64.3% to 7411763.0 in 2022, then declined by 29.47% to 9595700.0 in 2023, then declined by 13.73% to 10913478.0 in 2024, then surged by 60.19% to 4344136.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 4344136.0, 4275121.0, and 5115526.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.34 Mn |
| Dec 31, 2025 | -4.34 Mn |
| Sep 30, 2025 | -4.28 Mn |
| Sep 30, 2025 | -4.28 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Mar 31, 2025 | -9.38 Mn |
| Mar 31, 2025 | -9.38 Mn |
| Dec 31, 2024 | -10.91 Mn |
| Dec 31, 2024 | -10.91 Mn |
| Sep 30, 2024 | -9.17 Mn |
| Sep 30, 2024 | -9.17 Mn |
| Jun 30, 2024 | -14.14 Mn |
| Jun 30, 2024 | -14.14 Mn |
| Mar 31, 2024 | -13.36 Mn |
| Mar 31, 2024 | -13.36 Mn |
| Dec 31, 2023 | -9.60 Mn |
| Dec 31, 2023 | -9.60 Mn |
| Sep 30, 2023 | -8.07 Mn |
| Sep 30, 2023 | -8.07 Mn |